Evidence map›Paper›PMID 40803526›Full record

Trial reportJournal of vascular and interventional radiology : JVIR2025

Pilot Study of Combining Stereotactic Body Radiation Therapy with Pulsed Field Ablation for Oligometastatic/Oligoprogressive Lung Tumors.

Jeremy P Harris, Christina Boyd, Mengying Shi, Michael Reilly, Aaron Simon, Steven N Seyedin, Wen-Pin Chen, Misako Nagasaka, Rupali Nabar, Nadine Abi-Jaoudeh

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of vascular and interventional radiology : JVIR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05555342 (A Novel Method for Treating Lung Metastases With the Combination of Electrical Fields and Radiation Therapy), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05555342 early_phase1completednot on this map

A Novel Method for Treating Lung Metastases With the Combination of Electrical Fields and Radiation Therapy: A Single-Arm Pilot Study

TypeinterventionalSponsorUniversity of California, IrvineRan2023 to 2024Enrolled6ConditionsLung Tumor, Metastatic CancerArmsIrreversible electroporation (IRE) ablation, Radiation Therapy
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jeremy P HarrisDepartment of Radiation Oncology, University of California-Irvine, Orange, California. Electronic address: Jpharris1@uci.edu.
Christina BoydDivision of Vascular & Interventional Radiology, University of California-Irvine, Orange, California.
Mengying ShiDepartment of Radiation Oncology, University of California-Irvine, Orange, California.
Michael ReillyDepartment of Radiation Oncology, University of California-Irvine, Orange, California.
Aaron SimonDepartment of Radiation Oncology, University of California-Irvine, Orange, California.
Steven N SeyedinDepartment of Radiation Oncology, University of California-San Francisco, San Francisco, California.
Wen-Pin ChenDepartment of Medicine, University of California-Irvine, Orange, California.
Misako NagasakaDivision of Hematology & Oncology, University of California-Irvine, Orange, California.
Rupali NabarDivision of Hematology & Oncology, University of California-Irvine, Orange, California.
Nadine Abi-JaoudehDivision of Vascular & Interventional Radiology, University of California-Irvine, Orange, California.

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
NCI NIH HHS P30 CA062203
6 · The paper itself

Abstract

purposeTo evaluate the feasibility of combining pulsed field ablation through irreversible electroporation (IRE) or pulsed electric field (PEF) with stereotactic body radiation therapy (SBRT) delivered within 15 days for lung tumors. MATERIALS AND

methodsA prospective pilot study was designed for the treatment of lung tumors with pulsed field ablation followed by 12 Gy in 1 fraction. Percutaneous ablation via paired electrode probes (IRE) or a single-probe system (PEF) was allowed on the trial; the intent was complete ablation. Patients with oligometastatic or oligoprogressive cancer of any histology and 1-3 lung tumor targets of 1-6 cm were included. The primary end point was feasibility, while secondary end points were safety, local failure, progression-free survival, overall survival, and changes in lung function. This trial was registered with ClinicalTrials.gov (NCT05555342).

resultsSix patients with 8 tumors were enrolled and treated, including 3 ultracentral, 2 central, and 3 peripheral tumors. All patients completed treatment with PEF ablation (n = 0 with IRE) and SBRT, and 1 had a Grade ≥3 adverse event related to postprocedural extubation. Other adverse events were of Grade 1 (n = 3). There were no significant changes from baseline to 3 months in forced vital capacity (FVC, P = .68), forced expiratory volume in 1 second (FEV1, P = .16), or diffusing capacity of the lung for carbon monoxide (DLCO, P = .30). The median follow-up was 19 months, and there were 3 local failures in 2 patients. The 12-month rate of local failure was 37.5% (95% CI, 7%-69%), progression-free survival was 17% (95% CI, 3%-99%), and overall survival was 83% (95% CI, 58%-100%).

conclusionsCombining pulsed field ablation in this pilot trial was feasible and well-tolerated.

Indexed as

Ablation TechniquesLung NeoplasmsRadiosurgeryAgedAged, 80 and overDisease ProgressionElectroporationFeasibility StudiesFemaleHumansMaleMiddle AgedPilot ProjectsProgression-Free SurvivalProspective StudiesTime Factors

Identifiers

PMID40803526
PMCPMC12582577

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.